CoChat

Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients

Massimo, Berger, Giovanni, Grignani, Stefano, Ferrari, Eleonora, Biasin, Adalberto, Brach del Prever, Sandra, Aliberti, Francesco, Saglio, Massimo, Aglietta, Franca, Fagioli · 2009 · Cancer
Cited by 61

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: A phase 2 trial was carried out to assess the antineoplastic activity of 2 courses of cyclophosphamide‐etoposide in relapsed osteosarcoma patients. METHODS: Twenty‐six relapsed osteosarcoma patients with a median age of 18.5 years (8.3‐47.1) were enrolled. Seven patients were in first relapse (27%), 11 in second relapse (42%), 7 in third relapse (27%), and 1 in fourth relapse (4%). Eighteen patients had bone metastasis at study entry (69%). Cyclophosphamide was given at 4 g/m 2 on Day 1 followed by etoposide at 200 mg/m 2 on Days 2, 3, and 4. Second cyclophosphamide and etoposide was planned at 21 days to 28 days from the previous one. The primary endpoint of the study was the clinical benefit at 4 months measured as progression‐free survival. RESULTS: Progression‐free survival at 4 months was 42%. Five patients achieved responses (19%), 9 patients had stable disease (35%), and 12 had tumor progression (46%). Overall survival (OS) at 1 year was 50%. The only grade 4 extrahematological toxicities were fever (5%), acute bronchospasm (4%) and stomatitis (18%). Six patients (23%) underwent radical surgery after cyclophosphamide and etoposide ×2. CONCLUSIONS: Cyclophosphamide and etoposide ×2 may arrest osteosarcoma progression in a significant number of patients (54%). Osteosarcoma progression arrest after cyclophosphamide and etoposide ×2 translates in a better OS. Cyclophosphamide and etoposide ×2 had good tolerability and the toxicity was time‐limited and resolved in all cases. Cancer 2009. © 2009 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.24368

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 61

Metadata

Authors
Massimo, B., Giovanni, G., Stefano, F., Eleonora, B., Adalberto, B. D. P., Sandra, A., Francesco, S., Massimo, A., & Franca, F.
Venue
Cancer
Publisher
Wiley
Published
2009-05-18
Volume
115
Issue
13
Pages
2980-2987
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1975253840
Cited by
61
References
4
FWCI
2.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.